Huntington Disease: Clinical Features and Diagnosis
UptoDate Dec 2017, Oksana Suchowersky, 2017
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
Huntingtons Disease
BMJ 341:34-40, Novak,M.J. &Tabrizi,S.J., 2010
Predictors of Diagnosis in Huntington Disease
Neurol 68:1710-1717, Langbehn,D.R.,et al, 2007
The Association of CAG Repeat Length with Clinical Progression in Huntington Disease
Neurol 66:1016-1020, Rosenblatt,A.,et al, 2006
Functional Brain Changes in Presymptomatic Hunington's Disease
Ann Neurol 55:879-883, Reading,S.A.,et al, 2004
iH NMR Spectroscopy Studies of Huntington's Disease, Correlations with CAG Repeat Numbers
Neurol 50:1357-1365, Jenkins,B.G.,et al, 1998
Longitudinal Change in Basal Ganglia Volume in Patients with Huntington's Disease
Neurol 48:394-399, Aylward,E.H.,et al, 1997
CAG Repeat Number Governs the Development Rate of Pathology in Huntington's Disease
Ann Neurol 41:689-692, Penney,J.B.,et al, 1997
Relationship Between Trinucleotide Repeats and Neuropathological Changes in Huntington's Disease
Ann Neurol 39:132-136, Furtado,S.,et al, 1996
Trinucleotide Repeat Length and Clinical Progression in Huntington's Disease
Neurol 46:527-531, Brandt,J.,et al, 1996
Hereditary Late-Onset Chorea Without Significant Dementia:Genetic Evid for Phenotypic Variation in Huntington's Disease
Neurol 45:443-447, Britton,J.W.,et al, 1995
Juvenile Huntington Disease:CT and MR Features
AJNR 16:1405-1412, Ho,V.B.,et al, 1995
Reduced Basal Ganglia Volume Associated with the Gene for Huntington's Disease in Asymptomatic at-Risk Persons
Neurol 44:823-828, Aylward,E.H.,et al, 1994
Trinucleotide Repeat Length and Rate of Progression of Huntington's Disease
Ann Neurol 36:630-635, Illarioshkin,S.N.,et al, 1994
Trinucleotide Repeat Expansion in Neurological Disease
Ann Neurol 36:814-822, LaSpada,A.R.,et al, 1994
Clinical and Magnetic Resonance Features of the Classic & Akinetic-Rigid Variants of Huntington's Dis
Arch Neurol 50:17-19, Oliva,D.,et al, 1993
Putamen Volume Reduction on Magnetic Resonance Imaging Exceeds Caudate Changes in Mild Huntington's Disease
Ann Neurol 31:69-75, Harris,G.J.,et al, 1992
The Psychological Consequences of Predictive Testing for Huntington's Disease
NEJM 327:1401-1405, 14491992., Wiggins,S.,et al, 1992
Huntington's Disease Mortality in the United States
Neurol 38:769-772, Lanska,D.J.,et al, 1988
The Role of Glutamate in Neurotransmission & in Neurologic Disease
Arch Neurol 43:1058-1063, Greenamyre,J.T., 1986
Neuropeptides in Neurological Disease
Ann Neurol 20:547-565, Beal,M.F.&Martin,J.B., 1986
Levels of y-Aminobutyric Acid in Cerebrospinal Fluid in Various Neurologic Disorders
Arch Neurol 37:352-355, Manyam,N.V.B.,et al, 1980
Huntington Disease Associated with Alzheimer Disease
Ann Neurol 3:545, McIntosh,G.C.,et al, 1978
Huntington's Disease, CSF GABA Level in at-risk Individuals
Arch Neurol 35:728-730, Manyam,N.V.B.,et al, 1978
Identification of GABA in Human CSF by Gas Liquid Chromatography & Mass Spectrometry
NEJM 296:692, Huizinga,J.D.,et al, 1977
Treatment of Huntington's Chorea with Isoniazid
NEJM 297:840, 1977. (Letter), Perry,T.L.,et al, 1977